Australia's Chimeric Therapeutics rises on positive data for its cell therapy clinical trial

Chimeric Therapeutics

01/06/2026 05:16

** Shares of Australia's Chimeric Therapeutics CHM.AX rise as much as 40% to A$0.14, marking their biggest intraday pct gain since April 27 
** Stock hits its highest level since May 15
** The clinical stage cell therapy company announces positive Phase 1/2 data for its CHM CDH17 clinical trial 
** The Phase 1/2 trial is two-stage study designed to determine recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours
** Company says current update reflects additional patients treated, the commencement of Dose Level 3, translational data and longer follow-up
** About 582,942 shares change hands, 3.3x the 30-day average 
** Stock down 42.5%, YTD  


 (Reporting by Sneha Kumar in Bengaluru)
 ((Sneha.kumar@thomsonreuters.com;))